AAUM (Average Assets Under Management) of ₹361.15 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 38.7% | 39.8% | ▲ +1.1% |
| Healthcare Services | 8.7% | 11.0% | ▲ +2.3% |
| Telecom - Services | 9.6% | 10.8% | ▲ +1.2% |
| Food Products | 8.7% | 9.4% | ▲ +0.7% |
| Insurance | 3.7% | 0.0% | ▼ -3.7% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 39.8% | 53.6% | ▲ +13.8% |
| Food Products | 9.4% | 9.3% | ▼ -0.1% |
| Healthcare Services | 11.0% | 9.3% | ▼ -1.7% |
| Telecom - Services | 10.8% | 7.9% | ▼ -2.9% |
| Fertilizers & Agrochemicals | 0.0% | 0.3% | ▲ +0.3% |
Comparing Jun 2026 → Jul 2026
| # | Stock | Sector | Weight (Jul 2026) |
|---|---|---|---|
| 1 | IPCA Laboratories Limited ₹23.57 Cr |
Pharmaceuticals & Biotechnology | 5.93% |
| 2 | Sumitomo Chemical India Limited ₹1.30 Cr |
Fertilizers & Agrochemicals | 0.33% |
| # | Stock | Sector | Last Weight (Jun 2026) |
|---|---|---|---|
| 1 | Max Healthcare Institute Limited ₹7.92 Cr |
Healthcare Services | 2.03% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | GlaxoSmithKline Pharmaceuticals Limited ₹39.45 Cr |
Pharmaceuticals & Biotechnology | 2.04% | 9.93% | +7.89% |
| 2 | Concord Biotech Limited ₹38.35 Cr |
Pharmaceuticals & Biotechnology | 8.84% | 9.66% | +0.82% |
| 3 | Pfizer Limited ₹23.13 Cr |
Pharmaceuticals & Biotechnology | 5.44% | 5.82% | +0.38% |
| 4 | Aster DM Healthcare Limited ₹36.72 Cr |
Healthcare Services | 8.96% | 9.25% | +0.29% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | HFCL Limited ₹31.35 Cr |
Telecom - Services | 10.76% | 7.89% | -2.87% |
| 2 | SMS Pharmaceuticals Limited ₹28.89 Cr |
Pharmaceuticals & Biotechnology | 8.15% | 7.27% | -0.88% |
| 3 | Strides Pharma Science Limited ₹10.48 Cr |
Pharmaceuticals & Biotechnology | 2.86% | 2.64% | -0.22% |
| 4 | Zydus Wellness Limited ₹37.06 Cr |
Food Products | 9.44% | 9.33% | -0.11% |
| 5 | Alivus Life Sciences ₹28.57 Cr |
Pharmaceuticals & Biotechnology | 7.28% | 7.19% | -0.09% |
| 6 | Aurobindo Pharma Limited ₹20.41 Cr |
Pharmaceuticals & Biotechnology | 5.21% | 5.14% | -0.07% |
12 stocks — Jul 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹39.45 Cr |
Pharmaceuticals & Biotechnology |
9.93%
|
|
| 2 |
₹38.35 Cr |
Pharmaceuticals & Biotechnology |
9.66%
|
|
| 3 |
₹37.06 Cr |
Food Products |
9.33%
|
|
| 4 |
₹36.72 Cr |
Healthcare Services |
9.25%
|
|
| 5 |
₹31.35 Cr |
Telecom - Services |
7.89%
|
|
| 6 |
₹28.89 Cr |
Pharmaceuticals & Biotechnology |
7.27%
|
|
| 7 |
₹28.57 Cr |
Pharmaceuticals & Biotechnology |
7.19%
|
|
| 8 |
₹23.57 Cr |
Pharmaceuticals & Biotechnology |
5.93%
|
|
| 9 |
₹23.13 Cr |
Pharmaceuticals & Biotechnology |
5.82%
|
|
| 10 |
₹20.41 Cr |
Pharmaceuticals & Biotechnology |
5.14%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.